Ozempic and Thyroid Cancer: What the Boxed Warning Says and What Human Data Show

The video is fifteen seconds long. A hand holds up a folded package insert, a thumb pointing at a black-bordered paragraph, and a caption reads: “They don’t tell you this part.” Millions of views later, “ozempic thyroid cancer” is once again one of the fastest-climbing health searches in the United States, as of mid-2025.

What the video leaves out is almost everything that matters. The paragraph in the black box is real. So is the reason it exists, and so is a growing pile of human research, most of it published since 2023, that tells a more nuanced story than either the alarm or the reassurance camps admit. A single sentence written for rodents has been asked to carry a weight it was never designed for.

This piece walks through what the warning literally says, why regulators put it there, what the largest studies in people have found and how confident we can be in them. It also answers the questions people are quietly typing at midnight: whether thyroid trouble rules the drug out, whether thyroid cancer can itself cause weight loss, and what a diagnosis usually means today.

What changed recently: the dates behind the ozempic thyroid cancer searches

Nothing about the boxed warning itself has changed since Ozempic was approved for type 2 diabetes in December 2017. What changed is the volume of human data sitting alongside it, and the size of the population taking the medicine. A prescription written for a few hundred thousand people with diabetes now reaches millions, many of them using semaglutide for weight management under the Wegovy brand. Rare risks matter more when the denominator gets that large.

Three dated developments explain the current spike in interest.

• January 2023. A French national case-control study (Bezin and colleagues, published in Diabetes Care) reported that people with type 2 diabetes who had used a GLP-1 receptor agonist for one to three years had a roughly 58 percent higher relative odds of a thyroid cancer diagnosis than non-users. It was the first large signal in humans, and it traveled fast.
• October 2023. The European Medicines Agency’s safety committee completed a review of the class and concluded that the available evidence did not support a causal link between GLP-1 receptor agonists and thyroid cancer. European labels, which never carried a boxed warning, were left unchanged.
• April 2024. A Scandinavian cohort study of about 145,000 GLP-1 users in Denmark, Norway and Sweden (Pasternak and colleagues, BMJ) found no increased thyroid cancer risk compared with people taking another diabetes drug class, over an average of almost four years of follow-up.

Since then, tirzepatide (Mounjaro, Zepbound) has joined the market with the same class warning, several meta-analyses of randomized trials have been published, and short-form video has rediscovered the black box roughly every quarter. The US label, reproduced on MedlinePlus, still opens with the rodent finding and still advises patients to report specific neck symptoms. That mismatch between a stern label and reassuring cohort data is the real story, and it is why the question refuses to settle.

What the Ozempic boxed warning on thyroid tumors actually says

A boxed warning, sometimes called a black box, is the strongest safety notice the US Food and Drug Administration can require on a prescription label. It sits at the top of the prescribing information in a bordered box so that it cannot be missed.

The semaglutide warning makes four distinct points, and it helps to separate them because the viral summaries usually blur them into one.

• In rodents, semaglutide caused thyroid C-cell tumors. This is stated as established fact, because it is.
• Whether the drug causes C-cell tumors, including medullary thyroid carcinoma, in humans is unknown. The relevance of the rodent finding to people “has not been determined.” That is the label’s own phrasing, and it is deliberately agnostic.
• The medicine is contraindicated, meaning it should not be prescribed at all, for anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Prescribers should counsel patients about the potential risk and about symptoms of thyroid tumors.

Notice what the box does not say. It does not say semaglutide causes thyroid cancer in humans. It does not mention the common types of thyroid cancer, papillary and follicular, at all. It concerns a specific cell type, the C-cell, and a specific rare cancer that arises from it. The label also adds, outside the box, that routine blood tests for calcitonin or routine thyroid ultrasound are “of uncertain value” for early detection in people taking the drug, a point that surprises many readers who assume monitoring would be standard.

The same language appears, nearly word for word, on liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), semaglutide in all its forms (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound). It is a class warning. Any article implying that Ozempic is uniquely flagged is misreading the paperwork.

Why rats developed thyroid tumors: the C-cell story

Before any new medicine is approved, it is given to rodents at various exposures for up to two years to see what happens to their tissues. In those studies, both rats and mice given semaglutide developed more C-cell adenomas and carcinomas than untreated animals, and the effect grew with dose and duration. That finding was consistent across the GLP-1 class, appearing first with liraglutide in the late 2000s, which is why the FDA had a template ready.

C-cells, also called parafollicular cells, are a minority population in the thyroid gland that make a hormone called calcitonin, which plays a modest role in calcium regulation. They are scattered among the far more numerous follicular cells that produce thyroid hormone. The distinction matters because GLP-1 receptors, the proteins the drug latches onto, sit on C-cells, not follicular cells.

Here is where species diverge sharply.

• Rodent C-cells are densely studded with GLP-1 receptors. When the drug binds, calcitonin release rises, the cells proliferate, and over months some of that proliferation turns neoplastic.
• Human and monkey C-cells express very few GLP-1 receptors. In monkeys treated with liraglutide for more than a year at exposures far above human doses, calcitonin did not rise and no C-cell changes were seen.
• Rodents also have proportionally more C-cells to begin with, and spontaneously develop C-cell tumors at higher background rates than people do.

None of this proves safety in humans. Biology is full of surprises that species comparisons failed to predict. What it does mean is that the rodent finding has a plausible mechanism that may not translate. Regulators chose to warn anyway, and to make the warning a permanent, prominent one, because a rare cancer developing over decades is exactly the kind of harm that short clinical trials cannot exclude. The box is a statement about uncertainty, written in the language of caution.

Medullary thyroid carcinoma and MEN 2: the conditions that rule the drug out

Medullary thyroid carcinoma is a cancer of the calcitonin-producing C-cells. It is uncommon, accounting for only a few percent of all thyroid cancers, which are themselves relatively rare at roughly 44,000 new US cases a year. Most people who hear “thyroid cancer” are picturing the papillary type, which behaves very differently and has nothing to do with C-cells.

About one in four medullary cases runs in families, caused by an inherited change in a gene called RET. Multiple Endocrine Neoplasia type 2 is the name for the inherited syndrome in which that RET change predisposes a person to medullary thyroid cancer along with tumors of the adrenal glands and, in some subtypes, the parathyroid glands. People with MEN 2 often have their thyroid removed preventively in childhood because the lifetime risk of medullary cancer approaches 100 percent.

The contraindication is built around a straightforward piece of reasoning. If a drug stimulates C-cells in any species, the people you least want exposed to it are those whose C-cells are already primed to become cancerous. The label therefore names two groups.

• Anyone who has personally had medullary thyroid carcinoma.
• Anyone with a family history of MTC or a known diagnosis of MEN 2 in the family.

A family history of the far more common papillary or follicular thyroid cancer does not trigger the contraindication, although a prescriber will still want to know about it. Neither does a personal history of thyroid nodules, hypothyroidism or Hashimoto’s disease, as later sections explain.

In practice, this is why the intake questionnaire before a first prescription asks specifically about medullary cancer, MEN 2 or a relative who had thyroid cancer at an unusually young age. If you are unsure which type ran in your family, that is worth clarifying with relatives or old medical records before the appointment. Vague answers tend to produce either unnecessary refusals or, less often, prescriptions that should not have been written.

What the evidence actually says about GLP-1 thyroid cancer risk in humans

Medical evidence comes in grades. Randomized controlled trials, in which people are assigned by chance to drug or placebo, are the most trustworthy because they balance out hidden differences. Observational studies, which watch what happens to people who chose or were prescribed a drug, are larger and longer but vulnerable to bias. Animal studies and expert opinion sit lower still for questions about human risk. Here is how the semaglutide thyroid cancer question stacks up across those tiers.

Evidence type	What it found	Strength and limits
Rodent carcinogenicity studies	Dose- and duration-dependent C-cell tumors in rats and mice	Consistent and reproducible, but species differ in C-cell receptor biology
Randomized trials (pooled)	Thyroid cancer cases were rare in both drug and placebo arms; pooled estimates lean slightly upward with confidence intervals that include no effect	Highest quality design, but trials last two to five years and were not powered to detect a rare cancer
French case-control study, 2023	About 1.5- to 1.8-fold higher odds of thyroid cancer diagnosis, including medullary, with one to three years of use	Large and national, but observational; detection bias is a strong alternative explanation
Scandinavian cohort, 2024	No increased risk versus a comparator diabetes drug (hazard ratio 0.93) over about four years	Large, well-controlled, active comparator; still observational and still short for a slow cancer
Regulatory reviews	US boxed warning retained; European review found no causal link established	Expert synthesis of the above; reflects precaution as much as evidence

Read together, the human data are best described as reassuring but not yet conclusive. The strongest individual studies point toward no meaningful increase in risk. The residual uncertainty is about time: thyroid cancers can take a decade or more to become detectable, and no cohort has followed users that long. That is a real limitation, not a technicality, and an honest answer keeps it in view.

Why one study found a signal and another did not

Two large European studies, published fifteen months apart, reached opposite conclusions. That is not a scandal. It is a useful lesson in how observational research can mislead, and it explains why specialists treat the 2024 result as the more informative of the two.

The French study compared people diagnosed with thyroid cancer to matched controls without it, then looked backward at who had taken a GLP-1 drug. Users were more likely to have been diagnosed. The most persuasive alternative to a causal explanation is detection bias, sometimes called surveillance bias. People starting a drug with a thyroid warning on the label are examined more often, asked about their necks more often, and sent for ultrasound more often. Thyroid cancer is notoriously easy to find when you look: autopsy series have shown tiny, clinically silent papillary cancers in a meaningful share of adults who died of unrelated causes. Increase the looking and you increase the diagnosing, without changing the underlying disease.

Two details of the French data fit that pattern. The increase was concentrated in the first one to three years of use, when scrutiny is highest, rather than growing steadily with longer exposure as a true carcinogen usually would. And most of the excess cases were the common papillary type, which does not arise from the C-cells the drug acts on.

The Scandinavian study took a different approach. It compared new GLP-1 users to new users of another diabetes drug class, DPP-4 inhibitors, chosen because those patients had similar diabetes severity and similar contact with the healthcare system. With that comparator, the excess disappeared. The upper limit of the confidence interval ruled out a risk increase larger than about 31 percent. A sensitivity analysis against a third drug class, SGLT2 inhibitors, gave the same answer.

Neither study is perfect. But when a signal appears against a weak comparator and vanishes against a strong one, the more likely explanation is the comparator, not the drug. That is the current mainstream reading, and it is why regulators in Europe declined to escalate their warnings after the French paper.

Is it bad to take Ozempic if you have thyroid issues?

Most people asking this question have one of three conditions: an underactive thyroid (hypothyroidism), the autoimmune disease Hashimoto’s that usually causes it, or thyroid nodules found on a scan. None of these appears in the contraindication. The label rules out only a personal or family history of medullary thyroid carcinoma or MEN 2, and the common thyroid conditions are a different biological world.

Hypothyroidism involves the follicular cells that make thyroid hormone, not the C-cells the boxed warning concerns. There is no evidence that semaglutide worsens an underactive thyroid or makes Hashimoto’s more aggressive. Pooled trial data have hinted at slightly more thyroid-related adverse events of various kinds among GLP-1 users, but the finding is imprecise and does not point to any specific harm in people already living with hypothyroidism.

One practical interaction is worth knowing about. Semaglutide slows the emptying of the stomach, which can change how oral medicines are absorbed. Levothyroxine, the standard thyroid hormone replacement, is sensitive to absorption changes. Some people find their thyroid blood test (TSH) drifts after starting a GLP-1 drug, and substantial weight loss on its own can change thyroid hormone requirements. Clinicians managing both conditions often recheck thyroid levels in the months after the new medicine starts. Any adjustment to a thyroid prescription is a decision for the prescribing clinician, never something to do on your own.

Thyroid nodules deserve a slightly different answer. Nodules are extremely common, present in a large share of adults over 50 on ultrasound, and the vast majority are benign. Having nodules does not rule out the drug. It does mean a prescriber may want to know whether the nodules have already been evaluated, because a nodule that turns out to be medullary cancer would change the decision entirely. If an evaluation is pending, some clinicians prefer to complete it first.

People who have had their thyroid removed for papillary or follicular cancer are also not covered by the contraindication, though their oncology and endocrine teams should be part of the conversation.

What cancers are associated with Ozempic?

Thyroid cancer is the only cancer named in the semaglutide label. Two other concerns come up repeatedly in searches, and both deserve a plain answer.

Pancreatic cancer. Because GLP-1 drugs act on the pancreas and can rarely cause pancreatitis, early case reports raised the possibility of pancreatic cancer. Large randomized cardiovascular outcome trials, which together enrolled tens of thousands of participants, did not show an increase. Neither have the major observational cohorts. Pancreatitis remains a listed warning; pancreatic cancer does not. The evidence here is graded as reassuring, from both randomized and observational sources, with the usual caveat about follow-up length.

Breast cancer. An imbalance in breast cancer cases appeared in one early weight-management trial program for a different GLP-1 drug. Subsequent larger trials and meta-analyses have not confirmed a signal, and the leading interpretation is chance plus increased detection in women losing weight and undergoing more examinations.

There is another side to the ledger that the alarm videos never mention. Excess body weight is linked by the CDC and WHO to at least thirteen cancers, including endometrial, colorectal, kidney, liver, pancreatic and postmenopausal breast cancer. Observational studies published since 2023 have reported lower rates of several obesity-related cancers among GLP-1 users compared with people on other diabetes drugs. Those are observational findings and could reflect who gets prescribed the medicine rather than what it does. They are not proof that the drug prevents cancer, and no one should take it for that reason. They do illustrate that the question “does this raise cancer risk” has to be weighed against the risk that untreated obesity and diabetes already carry.

Every one of these threads shares the same limitation. Cancer is slow. The oldest large trials of GLP-1 drugs are barely a decade old, and mass use of semaglutide for weight is younger still. Confidence will grow with each year of registry follow-up, and honest sources will keep saying so.

Does semaglutide thyroid cancer risk apply to Wegovy, Mounjaro and Zepbound too?

Yes, on paper, and probably in biology. The boxed warning is not attached to the Ozempic brand but to the mechanism. Every approved medicine that activates the GLP-1 receptor for an extended period carries the same paragraph in the United States.

• Semaglutide sold as Wegovy (for weight management) or Rybelsus (a tablet for diabetes) has the identical warning to Ozempic, because it is the identical molecule.
• Tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight and obstructive sleep apnea, activates both the GLP-1 receptor and a second gut-hormone receptor called GIP. Rodent studies showed C-cell tumors with it as well, so it carries the warning.
• Liraglutide (Victoza, Saxenda) and dulaglutide (Trulicity) were among the first to carry it.

The human evidence discussed earlier comes mostly from the class as a whole rather than from semaglutide alone. The Scandinavian cohort, for instance, included liraglutide users as the largest single group, because it was on the market longest. That is a reasonable way to accumulate statistical power for a rare outcome, but it means the semaglutide-specific human data are thinner than the class data. Nothing suggests semaglutide behaves differently at the C-cell than its cousins, and its rodent findings were of the same kind.

Tirzepatide has the least human follow-up of any drug in the group, simply because it is newest. Its weight-management approval came in late 2023. Any confident statement about its long-term thyroid safety in people would be premature in either direction.

One related caution. Compounded semaglutide and tirzepatide, prepared by pharmacies rather than the original manufacturer, and so-called research-grade peptides marketed online are not FDA-approved products. They have not undergone the manufacturing review that approved medicines have, their contents can vary, and they are not intended for self-use. The safety data in this article apply to approved products taken under medical supervision.

Can thyroid cancer cause weight loss?

This question surfaces alongside the drug searches for an understandable reason: people losing weight on semaglutide sometimes wonder whether the loss could have another, more worrying cause. For thyroid cancer specifically, the answer is that unexplained weight loss is not a typical feature.

The confusion comes from a neighbor. An overactive thyroid, called hyperthyroidism, does cause weight loss, along with a racing heart, heat intolerance and anxiety, because excess thyroid hormone speeds up metabolism. Graves’ disease and overactive nodules are the usual culprits. Thyroid cancer, by contrast, almost never produces excess hormone. The great majority of thyroid cancers are discovered as a painless lump in the neck or, increasingly, as an incidental finding on a scan done for something else, in a person whose thyroid function is entirely normal.

Medullary thyroid carcinoma is a partial exception, not because it changes metabolism but because very high calcitonin levels in advanced disease can cause persistent diarrhea and flushing. That is a late feature of a rare cancer, not an early warning sign in a person otherwise well.

Substantial weight loss can accompany any advanced cancer through a process called cachexia, in which the body’s metabolism shifts toward breaking down muscle and fat. Thyroid cancer reaches that stage far less often than most cancers because it is usually caught early and treated effectively.

For someone on semaglutide, the weight loss itself is the intended pharmacological effect and, in the pivotal trials, averaged around 15 percent of starting body weight over 68 weeks in adults without diabetes. Weight loss that is faster than expected, accompanied by fever, night sweats, persistent pain or other symptoms that do not fit the drug’s known effects, is a reason for a conversation with the prescriber, whatever the cause turns out to be. The point is not to scan your body for cancer signs. It is to recognize that expected effects have a shape, and departures from that shape are worth mentioning.

How curable is thyroid cancer?

If the searches around this drug have any upside, it may be that more people learn how thyroid cancer actually behaves, because the popular image of cancer does not fit it well.

Thyroid cancer as a group has one of the highest survival rates of any cancer. In US national registry data compiled by the National Cancer Institute, the five-year relative survival across all types and stages is about 98 percent. For the most common papillary and follicular types found while still confined to the gland, it is close to 100 percent, and many patients treated decades ago are alive with no evidence of disease today. The word “cure” is used cautiously in oncology, but for early differentiated thyroid cancer, long-term freedom from disease after surgery is the expected outcome rather than the exception.

Outcomes differ by type.

• Papillary cancer, roughly 80 percent of cases, grows slowly and responds well to surgery, sometimes followed by radioactive iodine.
• Follicular cancer, the next most common, behaves similarly with slightly higher odds of spread through the bloodstream.
• Medullary cancer, the type in the boxed warning, does not take up radioactive iodine, so surgery is the main treatment. Survival is high when the cancer is confined to the thyroid and falls when lymph nodes or distant sites are involved. People with MEN 2 who have preventive surgery in childhood often avoid the cancer entirely.
• Anaplastic cancer, very rare and usually seen in older adults, is aggressive and has a much poorer prognosis. It is unrelated to C-cells.

Treatment choices, and whether a very small papillary cancer even needs immediate surgery versus careful monitoring, are individual decisions made with an endocrinologist and a thyroid surgeon. Nothing here predicts an individual outcome. The general lesson is that the cancer at the center of this controversy, if it ever did occur in a person because of a medicine, would in most forms be one of the more treatable diagnoses in oncology. That does not make the question unimportant. It does give it proportion.

Should people on Ozempic get calcitonin tests or thyroid ultrasounds?

It seems intuitive that a drug with a thyroid warning should come with thyroid monitoring. The label, and most specialist guidance, says otherwise, and the reasoning is worth understanding rather than simply accepting.

Calcitonin is the hormone C-cells make, and a very high level in the blood is a marker of medullary thyroid carcinoma. The label states that routine measurement of calcitonin in people taking semaglutide is of uncertain value for early detection. Several problems drive that judgment. Calcitonin can be mildly elevated for many benign reasons, including kidney disease, smoking, certain acid-reducing medicines and simply being male. A mildly raised result in a healthy person on a GLP-1 drug more often leads to anxiety, repeat testing and sometimes unnecessary biopsy than to a cancer diagnosis. The American Thyroid Association has taken a similar position, neither recommending for nor against routine testing because the evidence to support it does not exist.

Thyroid ultrasound has a different problem: it is too good at finding things. Population screening by ultrasound, tried at national scale in South Korea in the 2000s, produced a fifteen-fold rise in thyroid cancer diagnoses with no change in the number of people dying from the disease. Most of what was found would never have caused harm. Screening people on semaglutide would almost certainly reproduce that pattern and would make the detection-bias problem in observational studies worse, not better.

What clinicians do instead is targeted. A careful history before prescribing screens for the contraindication. An examination of the neck at routine visits, and attention to the specific symptoms listed on the label, catches the rare problem that does arise. A calcitonin test or ultrasound is ordered when there is a reason, such as a new lump or a family history that turns out to be more complicated than first reported.

If a clinician does order a baseline calcitonin, that is within their judgment and not wrong. Requesting one yourself, or seeking repeated scans for reassurance, is not supported by evidence and can set off a cascade of investigations. The decision rests with the prescriber who knows your history.

Common myths about Ozempic and thyroid cancer, corrected

The viral versions of this story tend to make a handful of claims. Each contains a grain of something true, wrapped in a conclusion the evidence does not support.

Myth: Ozempic has been proven to cause thyroid cancer in people. The rodent finding is proven. The human question is open, and the largest and best-controlled human study to date found no increased risk. “Proven” is not a word any regulator or major medical body has used.

Myth: The FDA is hiding the risk. The opposite is closer to the truth. The FDA requires the risk to be displayed in the most prominent format available on the label. It is on MedlinePlus, in the pharmacy leaflet and in every advertisement’s fine print. A warning that appears in a black box is the least hidden information in medicine.

Myth: Anyone with a thyroid problem cannot take it. The contraindication covers medullary thyroid carcinoma and MEN 2 only. Hypothyroidism, Hashimoto’s disease and benign nodules are not exclusions, though they warrant a conversation and sometimes closer blood-test monitoring.

Myth: The French study settled it. One observational study with a strong potential for detection bias, showing an effect concentrated in the early years of use and in a cancer type unrelated to the drug’s target cell, is a hypothesis, not a verdict. The follow-up cohort designed to test that hypothesis did not confirm it.

Myth: Europe pulled the warning, so it must be safe. Europe never had a boxed warning to pull; its label format differs. A 2023 European review found no causal link established, which is a statement about the current evidence, not a guarantee of safety.

Myth: Weight loss on the drug could be thyroid cancer. Thyroid cancer does not typically cause weight loss. Weight loss is the drug working as designed. Unusual patterns of weight loss still deserve a conversation, but not because of thyroid cancer specifically.

Correcting these is not the same as dismissing the concern. Long-term human data are incomplete, and saying so plainly is part of the honest version.

Putting the risk in proportion: what the numbers would mean if the signal were real

Absolute numbers change how a risk feels. Relative risks, the percentages that headlines love, do not tell you how likely something is, only how much likelier it is than some baseline. For a rare disease, even a genuinely doubled relative risk can translate to a small absolute change.

Start with the baseline. In the United States, about 14 people per 100,000 are diagnosed with thyroid cancer each year, and the lifetime risk of a diagnosis is roughly 1.2 percent. Medullary thyroid carcinoma, the type the warning concerns, accounts for only a few percent of that: fewer than one new case per 100,000 people per year.

Now imagine, purely as an exercise, that the highest estimate from the French study were true and that GLP-1 use raised the risk of medullary cancer by about 78 percent. Applied to a baseline of well under one case per 100,000 per year, that would mean on the order of one additional medullary cancer for every few hundred thousand people treated for a year. Set against a population in which the medicine is being taken for diabetes or obesity, conditions that themselves carry substantial risks of heart disease, kidney disease and several cancers, that is a small number. And the better-designed 2024 cohort suggests the true figure may be zero.

None of this is an argument for complacency. Rare harms accumulate when millions are exposed, and a harm that emerges after fifteen years would not yet be visible in any dataset. It is an argument for proportion. The realistic range of possibilities runs from “no effect” to “a small effect on a rare, usually treatable cancer,” not from “safe” to “causes cancer.”

For an individual, the arithmetic is different again. Someone with MEN 2 has a lifetime medullary cancer risk near 100 percent without the drug, which is exactly why the contraindication exists. Someone with no family history and normal thyroid function starts from a very low baseline. The right question is rarely “is this drug safe” in the abstract. It is “what does this drug change for me, given everything else on my chart,” and that question belongs in the consulting room.

When to see a doctor

The semaglutide label asks prescribers to counsel patients about the signs of a thyroid tumor and tells patients to report them. This is not an invitation to self-diagnose or to examine your neck every morning. It is a short list of red flags that should prompt a call to your prescribing clinician rather than a search engine.

Contact your clinician promptly if you notice:

• A lump or swelling in the front of the neck that is new or growing.
• Difficulty swallowing that persists rather than resolving over a few days.
• Shortness of breath that has no other obvious explanation.
• Hoarseness or a voice change lasting more than two to three weeks.

These symptoms have many causes, the overwhelming majority benign, and they are listed on the label because they are the way thyroid tumors of any kind usually announce themselves, not because they are common on the drug. A clinician will typically examine the neck and decide whether an ultrasound or blood test is warranted.

Separate from the thyroid, the same medicine carries warnings that call for urgent attention: severe, persistent abdominal pain that may spread to the back, with or without vomiting, which can signal pancreatitis; symptoms of gallbladder disease such as pain in the upper right abdomen with fever or yellowing of the skin; signs of an allergic reaction including facial swelling or trouble breathing; and, for people also taking insulin or sulfonylureas, symptoms of low blood sugar. Sudden vision changes in people with diabetic eye disease should also be reported.

Before starting the medicine, see your clinician to discuss any personal or family history of thyroid cancer, and try to learn which type it was. During treatment, keep scheduled follow-up visits even when the medicine is going well; that is where the neck examination and any thyroid blood tests happen.

One firm rule applies throughout. Do not stop, pause or change the dose of semaglutide or any thyroid medicine because of something you read or watched. Every one of those decisions has consequences for blood sugar, weight and thyroid balance, and every one belongs to the clinician who prescribed it.

How to talk to your prescriber about the thyroid warning

The most useful outcome of a scare is a better conversation. Prescribers expect to be asked about the boxed warning, and the exchange goes best when both sides arrive with specifics rather than a general sense of unease.

Come prepared with your own history. Has anyone in your family had thyroid cancer, and if so, do you know which type, at what age, and whether it was linked to an inherited syndrome? Have you ever had a thyroid ultrasound, a nodule biopsy or a calcitonin test? Are you taking levothyroxine or any other thyroid medicine? These facts, more than any published study, determine whether the warning applies to you.

Then ask the questions that actually help.

• Given my history, does the contraindication apply to me or to anyone in my family who might be considering this class of drugs?
• Should my thyroid function be rechecked after I start, particularly if I take thyroid hormone replacement?
• Which symptoms do you want me to call about, and how quickly?
• How does this risk compare with the risks of leaving my diabetes or weight where they are?

You may hear an honest “we do not know” in reply to questions about risk after twenty years of use. That answer is correct and should raise your confidence in the clinician rather than lower it. What the evidence supports, as of mid-2025, is that the human studies so far are reassuring, that the warning is grounded in rodent biology that may not apply to people, that specific rare conditions rule the drug out entirely, and that a handful of symptoms deserve prompt attention.

What matters most, in this writer’s reading of the evidence, is the history-taking before the first prescription. That single step is where the contraindication is caught, where a family’s forgotten diagnosis surfaces, and where an anxious person with Hashimoto’s learns that the warning was never about them. It costs nothing but a few honest questions, and it does more to protect people than any amount of scanning afterward.

Frequently asked questions

Does semaglutide cause thyroid cancer in humans?

It has not been shown to. Semaglutide causes thyroid C-cell tumors in rodents, which is why the US label carries a boxed warning, but the label states that relevance to people is unknown. The largest human studies, including a 2024 Scandinavian cohort of about 145,000 GLP-1 users, found no increased thyroid cancer risk over roughly four years. Longer follow-up is still needed before anyone can call the question closed.

Is it bad to take Ozempic if you have thyroid issues?

Common thyroid conditions do not rule it out. The contraindication applies only to a personal or family history of medullary thyroid carcinoma or MEN 2. Hypothyroidism, Hashimoto’s disease and benign nodules are not exclusions. People taking levothyroxine may need their thyroid blood tests rechecked after starting, because semaglutide slows stomach emptying and weight loss can change hormone needs. Any adjustment is the prescribing clinician’s decision.

What cancers are associated with Ozempic?

Thyroid cancer is the only cancer named in the label, based on rodent data. Early concerns about pancreatic and breast cancer have not been confirmed in large randomized trials or cohort studies. Observational data have reported lower rates of several obesity-related cancers among GLP-1 users, though those findings could reflect who is prescribed the drug rather than a protective effect. Long-term follow-up remains limited for all of these questions.

How curable is thyroid cancer?

Most thyroid cancers are highly treatable. US registry data show a five-year relative survival of about 98 percent across all types, and close to 100 percent for papillary and follicular cancers confined to the gland. Medullary thyroid carcinoma, the type in the boxed warning, has high survival when caught early and lower survival once it has spread. Anaplastic cancer, which is very rare, has a much poorer outlook. Individual prognosis depends on type and stage.

Can thyroid cancer cause weight loss?

Not typically. Weight loss is a feature of an overactive thyroid, not of thyroid cancer, which almost never produces excess hormone. Most thyroid cancers are found as a painless neck lump or incidentally on a scan in someone with normal thyroid function. Advanced medullary cancer can cause diarrhea and flushing through high calcitonin levels, and very advanced cancer of any kind can cause weight loss, but these are late features of uncommon situations.

What is the glp-1 thyroid cancer risk according to randomized trials?

Pooled analyses of randomized trials show that thyroid cancer was rare in both drug and placebo groups, with pooled estimates that lean slightly upward but have confidence intervals including no effect. Randomized trials are the strongest design, but they last two to five years and were never powered to detect a rare, slow-growing cancer. That is why large registry cohorts, despite their observational weaknesses, add essential information about longer-term risk.

Why is there a boxed warning if human studies are reassuring?

Because the warning reflects uncertainty, not proof of harm. Regulators saw a consistent, dose-dependent tumor signal in two rodent species and could not exclude a similar effect in people from short clinical trials. A boxed warning ensures the finding is communicated to every prescriber and patient while human data accumulate. The European regulator, using a different label format, reviewed the class in 2023 and found no causal link established.

Who exactly should not take semaglutide because of thyroid cancer?

Anyone who has personally had medullary thyroid carcinoma, and anyone with a family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Those are the only thyroid-related contraindications in the label. A family history of the far more common papillary or follicular thyroid cancer is not a contraindication, though prescribers will want to know about it. If you are unsure which type a relative had, clarify before your appointment.

Should I get a calcitonin blood test before or during treatment?

Routine testing is not recommended. The label states that routine calcitonin measurement or thyroid ultrasound is of uncertain value for early detection in people taking semaglutide, and thyroid specialists have taken a similar position. Calcitonin can be mildly raised for benign reasons, and screening ultrasound finds many harmless lesions. Clinicians order these tests when there is a specific reason, such as a new neck lump or a complicated family history.

Does the medullary thyroid carcinoma warning apply to Mounjaro and Zepbound too?

Yes. Tirzepatide, sold as Mounjaro and Zepbound, activates the GLP-1 receptor along with a second gut-hormone receptor and produced C-cell tumors in rodents, so it carries the same boxed warning and the same contraindication for medullary thyroid carcinoma and MEN 2. Because it reached the market more recently, tirzepatide has the least long-term human follow-up of any drug in the class, so confident statements about its thyroid safety are premature in either direction.

References

• Semaglutide Injection – MedlinePlus Drug Information (boxed warning and contraindications)
• Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study (BMJ, 2024) – PubMed
• Thyroid cancer – NHS

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.